VRDN - Viridian Therapeutics, Inc.
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$38.13
DETAILS
HIGH:
$50.00
LOW:
$26.00
MEDIAN:
$36.50
CONSENSUS:
$38.13
UPSIDE:
121.17%
About Viridian Therapeutics, Inc. (https://www.viridiantherapeutics.com)
Viridian Therapeutics, Inc., a biotechnology company, develops treatments for patients suffering from serious diseases. It develops VRDN-001, a humanized monoclonal anti-IGF-1R antibody that is in Phase 1/2 clinical trial for the treatment of thyroid eye disease (TED); VRDN-002, an IGF-1R antibody, which is in Phase 1 clinical trial; and VRDN-003, a therapeutic antibody targeting IGF-1R for the treatment of TED. The company was formerly known as Miragen Therapeutics, Inc. and changed its name to Viridian Therapeutics, Inc. in January 2021. Viridian Therapeutics, Inc. was founded in 2006 and is headquartered in Waltham, Massachusetts.
Key Executives
| NAME | TITLE | DOB | SALARY |
|---|---|---|---|
| Stephen F. Mahoney | Chief Executive Officer, President & Director | 1971 | $1,336,438 USD |
| Thomas W. Beetham | Chief Operating Officer | 1970 | $972,976 USD |
| Radhika Tripuraneni | Chief Medical Officer | 1980 | $840,686 USD |
| Jennifer Tousignant | Chief Legal Officer & Corporate Secretary | 1973 | $819,951 USD |
| Seth Harmon | Chief Financial Officer | 1981 | $785,651 USD |
| Anthony Casciano | Chief Commercial Officer | 1977 | – |
| Eric N. Olson | Co-Founder & Chairman of Scientific Advisory Board | – | – |
| Marvin H. Caruthers | Co-Founder & Scientific Advisory Board Member | 1940 | – |
| Melissa Manno | Chief Human Resources Officer | – | – |
| Michael R. Bristow | Co-Founder & Member of the Scientific Advisory Board | 1945 | – |
| Vahe Bedian | Co-Founder & Scientific Advisor | – | – |